Skip to main content

Table 4 Study participant disposition by individual study

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Study Treatment Randomized ITT mITT Total
030 Placebo 101 (100.0 %) 93 (92.1 %) 93 (92.1 %) 101
Tafenoquine 200-mg weekly 104 (100.0 %) 100 (96.2 %) 99 (95.2 %) 104
Mefloquine 200-mg weekly 101 (100.0 %) 96 (95.0 %) 96 (95.0 %) 101
043 Placebo 62 (100.0 %) 61 (98.4 %) 60 (96.8 %) 62
Tafenoquine 400-mg load only 64 (100.0 %) 60 (93.8 %) 57 (89.1 %) 64
Tafenoquine 200-mg weekly 61 (100.0 %) 55 (90.2 %) 55 (90.2 %) 61
Tafenoquine 400-mg weekly 62 (100.0 %) 59 (95.2 %) 57 (91.9 %) 62
045 Placebo 96 (100.0 %) 94 (97.9 %) 94 (97.9 %) 96
Tafenoquine 25-mg weekly 95 (100.0 %) 93 (97.9 %) 93 (97.9 %) 95
Tafenoquine 50-mg weekly 94 (100.0 %) 93 (98.9 %) 91 (96.8 %) 94
Tafenoquine 100-mg weekly 94 (100.0 %) 94 (100.0 %) 94 (100.0 %) 94
Tafenoquine 200-mg weekly 94 (100.0 %) 93 (98.9 %) 91 (96.8 %) 94
Mefloquine 250-mg weekly 48 (100.0 %) 46 (95.8 %) 46 (95.8 %) 48
  1. Percentages are based on the number of randomized study participants in each treatment group of each study
  2. ITT intent-to-treat, mITT modified intent-to-treat